Shareholders question looming patent cliff and antitrust risks in potential $400bn tie-up with Bristol Myers Squibb
Finance Financial Times Aug 3, 2026
AstraZeneca investors raise concerns over mega-merger talks
Shareholders question looming patent cliff and antitrust risks in potential $400bn tie-up with Bristol Myers Squibb
